-
公开(公告)号：EP3308798A3
公开(公告)日：2018-05-30
申请号：EP17203789.7
申请日：2013-06-06
发明人： YUAN, Quan , ZHANG, Tianying , LUO, Wenxin , CHEN, Yixin , ZHANG, Jun , XIA, Ningshao
IPC分类号： A61K39/12
摘要： The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositons for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.
-
公开(公告)号：EP2594579B1
公开(公告)日：2015-04-15
申请号：EP11806304.9
申请日：2011-07-15
发明人： LI, Shaowei , WEI, Minxi , KONG, Xianglin , WANG, Yingbin , ZHANG, Jun , XIA, Ningshao
CPC分类号： C07K14/005 , A61K38/00 , A61K39/12 , A61K2039/5258 , A61K2039/585 , C12N7/00 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034
摘要： Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
-
23.发明公开TRUNCATED HUMAN PAPILLOMAVIRUS TYPE 33 PROTEIN L1 有权VERKÜRZTESL1-PROTEIN DES HUMANEN PAPILLOMAVIRUS VOM TYP 33
公开(公告)号：EP2716653A1
公开(公告)日：2014-04-09
申请号：EP12788749.5
申请日：2012-05-22
发明人： LI, Shaowei , KONG, Xianglin , WEI, Minxi , PAN, Huirong , ZHANG, Jun , XIA, Ningshao
IPC分类号： C07K14/025 , C12N15/37 , C12N15/63 , C12N7/04 , C07K1/16 , C07K1/30 , A61K39/12 , A61P31/20 , A61P35/00
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5258 , A61K2039/55566 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034
摘要： The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.
摘要翻译： 本发明涉及33型人乳头状瘤病毒（HPV）的截短的L1蛋白，其编码序列，其制备方法以及包含其的病毒样颗粒，其中蛋白质和病毒样颗粒 可用于预防HPV（特别是HPV33）感染，以及由HPV（特别是HPV33）感染引起的疾病，如宫颈癌。 本发明还涉及蛋白质和病毒样颗粒在制备用于预防HPV（特别是HPV33）感染的药物组合物或疫苗以及由HPV（特别是HPV33）感染引起的疾病如宫颈癌中的用途 癌症。
-
公开(公告)号：EP4086274A1
公开(公告)日：2022-11-09
申请号：EP20909593.4
申请日：2020-12-25
发明人： LI, Tingdong , GE, Shengxiang , GUO, Xiaoyi , HONG, Congming , SONG, Liuwei , WEN, Shunhua , TANG, Jiabao , ZHANG, Jun , XIA, Ningshao
IPC分类号： C07K14/435 , C07K14/00 , G01N33/68 , G01N33/574 , G01N33/569
摘要： Provided are a method for diagnosing nasopharyngeal carcinoma on the basis of the anti-EB virus (EBV) antibody level and a kit used for the method. Also provided are a polypeptide encoded by a BNLF2b gene in EB virus used for the above-mentioned diagnosis and the use thereof for diagnosing nasopharyngeal carcinoma.
-
公开(公告)号：EP3296386B1
公开(公告)日：2020-05-06
申请号：EP16792183.2
申请日：2016-05-11
发明人： GE, Shengxiang , ZHANG, Shiyin , XU, Feihai , WANG, Jin , LI, Jinjie , ZHANG, Jun , XIA, Ningshao
-
公开(公告)号：EP3407071A1
公开(公告)日：2018-11-28
申请号：EP17741038.8
申请日：2017-01-18
发明人： GE, Shengxiang , LIU, Yongliang , CHEN, Mengyuan , ZHANG, Jun , XIA, Ningshao
IPC分类号： G01N33/68
CPC分类号： G01N33/68
摘要： Disclosed are a method for diagnosing whether a subject is suffering from active tuberculosis, a method for determining the therapeutic effect of a therapy on active tuberculosis, a method for screening a candidate drug capable of treating active tuberculosis, and a kit comprising a specific stimulating agent and a reagent for detecting the level of IL-6, the method and kit belong to the fields of molecular biology, immunology and disease diagnosis.
-
公开(公告)号：EP2899267B1
公开(公告)日：2018-10-10
申请号：EP13838213.0
申请日：2013-06-24
发明人： GE, Shengxiang , LI, Tingdong , GUO, Qingshun , XU, Feihai , ZHANG, Jun , XIA, Ningshao
CPC分类号： C12N7/00 , A61K38/162 , A61K39/00 , C12N7/04 , C12N2720/12322 , C12N2720/12323 , C12N2720/12333 , C12N2720/12334 , C12N2720/12352
摘要： The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.
-
28.发明公开NUCLEIC ACID AMPLIFICATION REACTION TUBE CAPABLE OF CONTROLLING LIQUID CIRCULATION PATH 审中-公开核酸扩增反应管可以控制液体循环路径
公开(公告)号：EP3296386A1
公开(公告)日：2018-03-21
申请号：EP16792183.2
申请日：2016-05-11
发明人： GE, Shengxiang , ZHANG, Shiyin , XU, Feihai , WANG, Jin , LI, Jinjie , ZHANG, Jun , XIA, Ningshao
摘要： Disclosed are a reaction tube for nucleic acid amplification capable of controlling a liquid circulation path, a reaction apparatus for nucleic acid amplification comprising the reaction tube, and a method for amplifying nucleic acid comprising a step of using the reaction tube. Also disclosed are a kit comprising the reaction tube, and use of the reaction tube in preparation of a kit.
摘要翻译： 本发明公开了一种能够控制液体循环路径的用于核酸扩增的反应管，包括该反应管的用于核酸扩增的反应装置以及一种用于扩增核酸的方法，该方法包括使用该反应管的步骤。 还公开了包含反应管的试剂盒以及使用反应管制备试剂盒。
-
29.发明公开METHOD FOR ASSESSING RISK OF HUMAN CYTOMEGALOVIRUS ACTIVE INFECTION IN BODY AND RELATED KIT 审中-公开评估体内和相关试剂盒中人巨细胞病毒活性感染风险的方法
公开(公告)号：EP3258265A1
公开(公告)日：2017-12-20
申请号：EP16748586.1
申请日：2016-01-26
申请人： Xiamen University
发明人： GE, Shengxiang , LI, Jinjie , HUANG, Xi , LI, Tingdong , ZHANG, Jun , XIA, Ningshao
IPC分类号： G01N33/53 , G01N33/569 , G01N33/543
CPC分类号： G01N33/56983 , G01N33/53 , G01N33/543 , G01N33/569 , G01N33/56994 , G01N2333/045 , G01N2469/20 , G01N2800/50 , G01N2800/52
摘要： The invention belongs to the fields of medicine and immunology, particularly, the field of immunological diagnosis. In particular, the invention discloses a method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection and a kit therefor. The method comprises the steps of: (1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and (2) comparing the level with a predetermined reference value, wherein if the level is below the predetermined reference value, the subject is determined to be at risk of developing HCMV active infection. In addition, the invention also discloses a method for screening a candidate drug which is capable of improving the ability of a subject to resist human cytomegalovirus (HCMV) active infection, and a kit therefor.
摘要翻译： 本发明属于医学和免疫学领域，特别是免疫学诊断领域。 特别地，本发明公开了评估受试者是否有发生人巨细胞病毒（HCMV）活性感染风险的方法及其试剂盒。 该方法包括以下步骤：（1）确定来自受试者的体液样品中针对HCMV蛋白的抗体水平; 和（2）将该水平与预定参考值进行比较，其中如果该水平低于预定参考值，则确定该受试者处于发生HCMV活动性感染的风险中。 此外，本发明还公开了用于筛选能够改善受试者抵抗人巨细胞病毒（HCMV）活性感染的能力的候选药物的方法及其试剂盒。
-
公开(公告)号：EP2589604B1
公开(公告)日：2016-10-05
申请号：EP11800199.9
申请日：2011-07-01
发明人： LI, Shaowei , MO, Xiaobing , WEI, Minxi , PAN, Huirong , ZHANG, Jun , XIA, Ningshao
IPC分类号： C07K14/025 , C12N15/70 , C12N1/21 , A61K39/12 , A61P31/20
CPC分类号： C07K14/025 , A61K39/0011 , A61K39/12 , A61K2039/5258 , A61K2039/585 , C07K14/005 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034 , C12N2710/20051 , C12P21/02
-
-
-
-
-
-
-
-
-
搜索结果
44 条记录 (耗时 0.025 秒)
